Mehmet Emin Kocabaş

Mehmet Emin Kocabaş

Auto-generated profile, based on publicly available information

Mehmet Emin Kocabaş

Department of Immunology and Allergy, İzmir City Hospital, Bayraklı, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Endocrinology Research and Practice
Verified
Journal Article
Open access
HDHüseyin DÖNGELLİ
Hüseyin DÖNGELLİ
MKMehmet Emin Kocabaş
Mehmet Emin Kocabaş
Takayasu arteritis (TA) is a rare, idiopathic, granulomatous large vessel arteritis that primarily affects the aorta and its branches. Diabetic ketoacidosis (DKA) represents the most common hyperglycemic emergency in individuals with diabetes mellitus. Triggering factors for DKA can include infections, trauma, acute pancreatitis, certain medications, and ischemic vascular events. Hereby a female patient in her 30s with type 1 diabetes, who presented with vague abdominal pain, nausea, and fatigue, is presented. Initial evaluation indicated findings consistent with DKA, including hyperglycemia, aci dosis, and ketonuria. No underlying conditions, such as infection, were identified. Although the DKA episode subsided, the severity of her abdominal pain intensified, and acute phase reactants were elevated. Abdominal computed tomography revealed thickening of the abdominal aortic wall, and aortic magnetic resonance angiography confirmed findings consistent with TA. Immunosuppressive treatment was initiated. During the 1-year follow-up, the patient experienced only 1 additional epi sode of DKA following the diagnosis of TA. To our knowledge this is the first reported case of Takayasu arteritis one manifesting as recurrent DKA attacks in the literature. Cite this article as: Döngelli H, Kocabaş ME. Takayasu arteritis presenting as recurrent diabetic ketoacidosis attacks in patient with type 1 diabetes mellitus. Endocrinol Res Pract. 2025;29(3):277-279.

14 September 2026 in İzmir Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
MKMehmet Emin Kocabaş
Mehmet Emin Kocabaş
Amaç: Çalışmamızın amacı soğuk teması ile tetiklenen alerjik semptomları olan erişkin hastalarda buz provokasyon testi sonuçlarını değerlendirmek; hastaların demografik, klinik ve laboratuvar özelliklerini tanımlayarak test pozitifliği ile klinik seyir arasındaki ilişkiyi ortaya koymaktır.Gereç ve Yöntemler: Çalışmaya 2024-2026 yılları arasında soğuk teması (hava, su, materyal) sonrası reaksiyon öyküsü olan ve buz provokasyon testi uygulanan 18 yaş üzeri 60 erişkin hasta dahil edildi. Ön kol iç yüzeyine plastik torba içinde buz küpü teması ile standart 5 dakika; yanıt alınamayan klinik şüpheli olgularda ise sırasıyla 10 ve 20 dakikalık uzatılmış provokasyon uygulandı. Test sonrasında 10 dakika içinde gelişen palpabl döküntü, kızarıklık ve kaşıntı pozitif kabul edildi. Hastalar buz testi sonucuna göre gruplandırılarak demografik, klinik ve laboratuvar verileri karşılaştırıldı.Bulgular: Altmış hastanın 23’ünde (%38) buz testi pozitif, 37’sinde (%62) negatif saptandı. Buz testi pozitif hastaların 11’inde (%47,8) 5. dakikada, 8’inde (%34,8) 10. dakikada ve 4’ünde (%17,4) 20. dakikada pozitiflik elde edildi. Anjioödem, solunum yakınmaları ve hipotansiyon/senkop pozitif grupta sayısal olarak daha sık görülmekle birlikte gruplar arasındaki fark istatistiksel olarak anlamlı değildi. Eozinofil, total IgE ve triptaz düzeyleri de pozitif grupta daha yüksek olmakla birlikte istatistiksel anlamlılık göstermedi. Test süresinin 20 dakikaya uzatılması, 5 veya 10. dakikada negatif olan 4 hastada (%17,4) ek tanısal katkı sağladı.Sonuç: Buz provokasyon testi pozitifliği, tanısal katılan bir bulgu olmanın yanı sıra, olası sistemik reaksiyon eğilimini değerlendirmede yardımcı bir parametre olarak düşünülebilir. Standard 5-10 dakikalık testlerle yanıt alınamayan yüksek şüpheli olgularda test süresinin 20 dakikaya uzatılması tanısal duyarlılığı artırmaktadır. Sistemik reaksiyon riski yüksek saptanan test pozitif hastalarda adrenalin oto-enjektörü reçetelenmesi ve biyolojik tedavi seçenekleri öncelikli olarak değerlendirilmelidir.Anahtar kelimeler: Soğuk Ürtikeri; Deri Testi; Kronik İndüklenebilir Ürtiker

1 May 2026 in Allergologia et Immunopathologia
Verified
Journal Article
Open access
PDF file
OSOrbay Tutku Seren
Orbay Tutku Seren
AGAYSU OKUMUS GUCLU
AYSU OKUMUS GUCLU
MKMehmet Emin Kocabaş
Mehmet Emin Kocabaş
BABetül Aksu
Betül Aksu
ÜÖÜmit Özmen
Ümit Özmen
PDPapatya bayrak degirmenci
Papatya bayrak degirmenci
Asthma–COPD overlap (ACO) remains therapeutically challenging, and evidence for biologic selection is limited due to the under-representation of overlap phenotypes in trials. We report a T2-high ACO patient who did not benefit from omalizumab or benralizumab but improved with dupilumab. This presents the case of a 67-year-old man with a long-term smoking history, atopy (elevated total IgE with polysensitization), eosinophilia, persistent airflow limitation, and frequent exacerbations despite optimized inhaled triple therapy. Sequential biologics included anti-IgE (omalizumab) and anti-IL-5Rα (benralizumab), with no meaningful reduction in exacerbations or improvement in lung function. After initiating dupilumab at a dose of 300 mg every 2 weeks, the patient reported a rapid improvement in symptoms, with no further exacerbations observed during the follow-up period. Pulmonary function showed a notable increase, with postbronchodilator FEV1 rising from 61 to 72% of the predicted value, and FEV1/FVC ratio improving from 69 to 84.5%. Asthma control scores increased from 12 to 20 by Week 12. Oral corticosteroid therapy was successfully discontinued, and no adverse events requiring discontinuation of dupilumab were recorded. In T2-high ACO unresponsive to anti-IgE and anti-IL-5Rα therapies, IL-4/IL-13 pathway inhibition with dupilumab may deliver a clinically meaningful benefit. Controlled studies are warranted to define its role in overlap phenotypes.

1 July 2026 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
OSOrbay Tutku Seren
Orbay Tutku Seren
AGAYSU OKUMUS GUCLU
AYSU OKUMUS GUCLU
MKMehmet Emin Kocabaş
Mehmet Emin Kocabaş
BABetül Aksu
Betül Aksu
ÜÖÜmit Özmen
Ümit Özmen
PDPapatya bayrak degirmenci
Papatya bayrak degirmenci
Management of chronic spontaneous urticaria (CSU) remains challenging due to frequent patient refractoriness to high-dose H1-antihistamines, necessitating omalizumab therapy. At diagnosis, reliable and accessible biomarkers are critical to predict which patients will require treatment escalation. This study aimed to evaluate baseline hematological parameters and derive inflammatory indices for their capacity to predict maximum H1-antihistamine dose and subsequent need for omalizumab in a homogenous CSU cohort without major comorbidities. This single-center, retrospective cohort study included 185 adult CSU patients. Baseline inflammatory markers were analyzed relative to the primary outcome of omalizumab requirement and secondary outcome of intensity of antihistamine dose. Multivariate logistic regression and receiver operating characteristic analyses identified independent predictors and optimized cut-off values. Higher baseline levels of inflammatory markers, such as white blood cell count, neutrophils, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and aggregate index of systemic inflammation (AISI), were significantly associated with the need for fourfold antihistamine dosing. Adjusted multivariate analysis identified AISI ≥ 346.8 (adjusted odds ratio [aOR] = 7.45) as an independent predictor of omalizumab requirement, while erythrocyte sedimentation rate (ESR) > 7.5 (aOR = 0.24) was identified as an independent protective factor against omalizumab requirement. As a standalone biomarker, AISI demonstrated an area under the curve (AUC) of 0.733 and a negative predictive value (NPV) of 96.4% at this threshold. In this cohort, baseline AISI was independently associated with omalizumab requirement and appears to be a promising marker that warrants external validation, whereas elevated ESR appears protective. Given the retrospective single-center design, these findings should be interpreted cautiously. A high NPV of the AISI cut-off suggests potential clinical utility for ruling out patients unlikely to require treatment escalation.